Reimbursement Review Reports

The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.

Brand Name Generic Name Sort ascending Therapeutic Area Recommendation Type Project Status Date Submission Received Date Recommendation Issued
Sublinox Zolpidem tartrate Insomnia Do not list Complete
Aclasta Zoledronic acid Osteoporosis, postmenopausal women Do not list Complete
Aclasta Zoledronic acid Osteoporosis List with clinical criteria and/or conditions Complete
Zeldox Ziprasidone hydrochloride Schizophrenia and related psychotic disorders List with clinical criteria and/or conditions Complete
TBC zilucoplan Generalized myasthenia gravis (gMG) Active
Brukinsa zanubrutinib Chronic lymphocytic leukemia /small lymphocytic lymphoma. Reimburse with clinical criteria and/or conditions Complete
Brukinsa zanubrutinib Mantle cell lymphoma (MCL) Do not reimburse Complete
Brukinsa zanubrutinib Waldenström’s macroglobulinemia Reimburse with clinical criteria and/or conditions Complete
Amvuttra vutrisiran Hereditary transthyretin mediated amyloidosis (hATTR amyloidosis) Reimburse with clinical criteria and/or conditions Active
Trintellix vortioxetine hydrobromide Major depressive disorder (MDD), adults. Reimburse with clinical criteria and/or conditions Complete